ORGANICELL

Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In COVID-19 Long Haulers

Retrieved on: 
Wednesday, July 21, 2021
COVID-19, Clinical research, Clinical trials, Long Covid, Health, Placebo-controlled study, Cough, Articles

This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.

Key Points: 
  • This approved trial design consists of a double blinded, placebo-controlled, randomized phase I/II trial designed to investigate the safety and potential efficacy of Zofin in treating COVID-19 long haulers.
  • These patients, called COVID-19 "long haulers," report lingering shortness of breath, cough, fatigue, and mental fog for months after recovery, impairing their return to work and everyday life.
  • Even by the lowest health care industry estimates, the magnitude of this secondary health crisis of COVID-19 long haulers will result in millions of affected individuals.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Organicell Welcomes Dr. George C. Shapiro To The Medical Advisory Board

Retrieved on: 
Monday, February 25, 2019
Shapiro, Surnames, Exosome complex, Genetics, Biology

In addition to serving on the Company's Advisory Board, Dr. Shapiro is assembling the medical advisory board for Organicell.

Key Points: 
  • In addition to serving on the Company's Advisory Board, Dr. Shapiro is assembling the medical advisory board for Organicell.
  • In addition to building a medical advisory board, Dr. Shapiro will play an instrumental role in the clinical trials for Organicell's new biologic medicines.
  • "We are honored that Dr. Shapiro agreed to join our Board of Directors," said Organicell CEO Manny Iglesias.
  • "He will be assembling a world-class medical advisory board to help guide the Company along the cutting-edge of medical science as we develop and test Exosome-based therapies."